Published On: Tue, Sep 6th, 2016

Research Analysts’ Weekly Ratings Updates for Intellia Therapeutics (NTLA)

Intellia Therapeutics (NASDAQ: NTLA) recently received a number of ratings updates from brokerages and research firms:

9/6/2016 – Intellia Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
8/30/2016 – Intellia Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
8/23/2016 – Intellia Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $38.00 price target on the stock.
8/17/2016 – Intellia Therapeutics had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $33.00 price target on the stock.
8/5/2016 – Intellia Therapeutics was upgraded by analysts at Jefferies Group from a “hold” rating to a “buy” rating. They now have a $33.00 price target on the stock.
8/5/2016 – Intellia Therapeutics was upgraded by analysts at Leerink Swann from a “market perform” rating to an “outperform” rating. They now have a $32.00 price target on the stock.
8/3/2016 – Intellia Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Intellia Therapeutics Inc (NASDAQ:NTLA) opened at 19.81 on Tuesday. Intellia Therapeutics Inc has a 12-month low of $17.05 and a 12-month high of $30.40. The company has a 50-day moving average price of $19.54 and a 200-day moving average price of $22.81. The firm’s market cap is $713.06 million.
Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Receive News & Ratings for Intellia Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>